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Abstract
Background: Metastasis is the leading cause of death among breast cancer patients. Identifying key cellular factors
controlling invasion and metastasis of breast cancer cells should pave the way to new therapeutic strategies
efficiently interfering with the metastatic process. PAX2 (paired box 2) transcription factor is expressed by breast
cancer cells in vivo and recently, it was shown to negatively regulate the expression of ERBB2 (erythroblastic
leukemia viral oncogene homolog 2, HER-2/neu), a well-documented pro-invasive and pro-metastastic gene, in
luminal/ERalpha-positive (ERa+) breast cancer cells. The objective of the present study was to investigate a
putative role for PAX2 in the control of luminal breast cancer cells invasion, and to begin to characterize its
regulation.
Results: PAX2 activity was higher in cell lines from luminal compared to non-luminal subtype, and activation of
PAX2 by estradiol was selectively achieved in breast cancer cell lines of the luminal subtype. This process was
blocked by ICI 182780 and could be antagonized by IGF-1. Knockdown of PAX2 in luminal MCF-7 cells completely
abrogated estradiol-induced downregulation of ERBB2 and decrease of cell invasion, whereas overexpression of
PAX2 in these cells enhanced estradiol effects on ERBB2 levels and cell invasion.
Conclusions: The study demonstrates that PAX2 activation by estradiol is selectively achieved in breast cancer cells
of the luminal subtype, via ERa, and identifies IGF-1 as a negative regulator of PAX2 activity in these cells. Further,
it reveals a new role for PAX2 in the maintenance of a low invasive behavior in luminal breast cancer cells upon
exposure to estradiol, and shows that overexpression and activation of PAX2 in these cells is sufficient to reduce
their invasive ability.
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Background
The heterogeneous nature of breast cancer is well estab-
lished. Based on their expression profile, breast tumours
are classified in five molecular subgroups (luminal A
a n dB ,b a s a l ,E R B B 2 -o v e r e x p r e s s i n g ,a n dn o r m a l - l i k e )
[1-3]; each is associated with distinct histological mar-
kers and clinical parameters. Only tumours of the lumi-
nal subgroups express the receptor alpha to estrogen
(ERa); however, luminal A tumours express higher
levels of ERa than luminal B tumours [1-3] and they are
associated with less aggressive metastatic disease and
longer disease-free survival [2]. In accordance, they
express low levels of ERBB2 (erythroblastic leukemia
viral oncogene homolog 2, HER-2/neu) in vivo [1], the
expression and activity of which confer invasive and
metastatic ability to breast cancer cells [4-7]. In vitro,
ERa+ lines such as MCF-7 and ZR-75-1, which were
d e r i v e df r o mE R a+/luminal A tumours, retain a mole-
cular profile characteristic of luminal A tumours, includ-
ing low expression of ERBB2 [8]; they also display poor
invasive and metastatic ability [3,8,9]. These cell lines
thus represent a good model to investigate the cellular
and molecular mechanisms underlying the poor invasive
and metastatic phenotype of luminal A tumours.
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of transcription factors, best known for their role in
terminal differentiation during organogenesis, at the
time of embryo development [10]. PAX2 is involved in
kidney and breast development [11,12], and although its
expression was initially thought to be silenced at the
end of the process [13], expression of PAX2 has been
found in adult, differentiated breast cells [14]. PAX2
expression was also detected in breast tumours:
although a relatively small number of samples have been
analyzed to date, PAX2 expression can equally be found
in different types of tumours [12,14-16]. On the other
hand, a differential regulation of PAX2 activation has
been evidenced between breast tumour subtypes:
nuclear localization of PAX2 is frequent in luminal
tumours and infrequent in non-luminal tumours [14,15].
Considering that luminal tumours are associated with
longest disease-free survival [2], and also that increased
nuclear localization of PAX2 in tumour cells negatively
correlates with tumour recurrence [15], preferential acti-
vation of PAX2 in poorly metastatic luminal breast can-
cer cells suggests that PAX2 activity confers protection
against metastasis in these tumours. Supporting this
hypothesis, a recent study has revealed that PAX2 nega-
tively regulates the expression of a well-established pro-
invasion and pro-metastastic gene, ERBB2 [5,6], in estra-
diol-treated luminal breast cancer cell lines [17]. A puta-
tive role for PAX2 as a negative regulator of invasion
and metastasis in breast cancer cells, however, has not
been pursued to this day.
In the present study, we have characterized the regula-
tion of PAX2 expression and activation in luminal and
non-luminal breast cancer cells; we also examined how
the modulation of PAX2 expression affects the invasive-
ness of estradiol-treated luminal breast cancer cells. Our
results show that in response to estradiol, PAX2 is phos-
phorylated and activated in breast cancer cells of the
luminal subtype selectively, via ERa; further, modulation
of PAX2 expression in these cells directly impacts their
invasive ability, in an ERa-dependent manner.
Results
To characterize PAX2 regulation in breast cancer cells,
we first compared basal expression and activation of
PAX2 between luminal and non-luminal cell lines.
PAX2 protein levels were similar in all tested cell lines
when cultivated in standard medium containing steroid
hormones and estradiol-mimicking molecules (Figure
1a), indicating that PAX2 expression does not differ
between the two cell subtypes. However, PAX2 phos-
phorylation on serine 393 residue, a marker of its activa-
tion [18], was higher in luminal/ERa+ cell lines (MCF-7
and ZR-75-1 cells [8]) compared to non-luminal/ERa-
cell lines (MDA-MB-231 and HS578T [8]) (Figure 1a,b),
showing preferential activation of PAX2 in luminal
breast cancer cells in vitro,a so b s e r v e din vivo [14,15].
The highest levels of phosphorylated PAX2 protein were
detected in the least invasive cell lines (luminal cell lines
MCF-7 and ZR-75-1 [8], Figure 1b), and negatively cor-
related with protein levels of ERBB2 (Figure 1b), a
major player in breast cancer cell invasion and metasta-
sis [5,6,19]: these results support the hypothesis that
PAX2 activation in luminal breast cancer cells maintains
a mild invasive and metastatic behavior.
Figure 1 PAX2 is activated in breast cancer cell lines of the luminal subtype selectively. Breast cancer cell lines of the luminal (MCF-7 and
ZR75-1) and non-luminal (MDA-MB-231 (231) and HS578T) subtypes were cultivated in their standard growth medium, containing growth factors,
steroid hormones and estradiol-mimicking molecules such as phenol red. A) Total levels of PAX2 protein, PAX2 phosphorylation on ser393
residue, and ERBB2 protein content were determined using western blot. GAPDH was used as a control to normalize for protein content. Results
are representative of three independent experiments. B) Densitometric analysis of the results presented in A. Values are mean +/-SD of three
independent experiments. Different subscript letters indicate a statistically significant difference.
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sure on the activation status of PAX2, in luminal and non-
luminal breast cancer cell lines. To this aim, breast cancer
cells were cultivated in a steroid- and serum-depleted
growth medium, before they were treated with exogenous
estradiol at concentrations known to activate estrogen-
responsive genes in luminal breast cancer cell lines such
as MCF-7 cells (100 nM or less) [20]. A 30-min treatment
with estradiol increased the levels of phosphorylation of
PAX2 protein on serine 393 residue in MCF-7 cells (Fig-
ure 2a), and induced the accumulation of PAX2 protein in
cell nucleus, as shown by immunofluorescence (Figure 2c)
and subcellular fractionation (Figure 2d). In addition, a
longer treatment with estradiol (24 hours) led to a reduc-
tion of ERBB2 protein levels in MCF-7 cells (Figure 2a), in
agreement with a previously described role for PAX2 in
the regulation of ERBB2 gene expression in these cells
upon treatment with estradiol [17]. Since estradiol treat-
ment had no impact on PAX2 expression, at the protein
(Figure 2a) or mRNA (Figure 2b) levels, these results indi-
cate that estradiol specifically regulates the activation of
PAX2 protein, but not PAX2 expression, in luminal breast
cancer cells. Treatment of non-luminal cell lines HS578T
and MDA-MB-231 with exogenous estradiol had no
impact on PAX2 phosphorylation and ERBB2 protein con-
tent (Figure 2e), showing that estradiol does not regulate
PAX2 activity in these cells. Collectively, these results indi-
cate that PAX2 activation in response to estradiol is selec-
tively achieved in breast cancer cells of the luminal
subtype.
By downregulating ERBB2 expression in luminal
breast cancer cells [17,21], estradiol could negatively
regulate their invasiveness; this question, however, had
not been directly examined to this day. We found that
overall invasion of MCF-7 cells was indeed reduced by
estradiol (Figure 3a). ICI 187280 (ICI) efficiently antago-
nizes ERa in these cells, as shown by long-term downre-
gulation of ERa expression (Figure 3b) [22,23]; in these
conditions, MCF-7 cell invasion was increased (Figure
3c), PAX2 phosphorylation was reduced (Figure 3d) and
ERBB2 protein levels were increased (Figure 3b),
whether the cells were subsequently treated with estra-
diol or not. Collectively, these results demonstrate a role
for ERa in basal and estradiol-induced PAX2 activation,
Figure 2 PAX2 is activated by estradiol in breast cancer cells of the luminal subtype selectively. Breast cancer cells were cultivated in a
steroid- and serum-depleted growth medium, before they were treated with estradiol. A) MCF-7 cells were treated for the indicated time
periods with 10 nM estradiol and total levels of PAX2 protein, PAX2 phosphorylation on ser393 residue, and ERBB2 protein levels were
determined using western blot. GAPDH was used as a control to normalize for protein content. B) MCF-7 cells were treated for the indicated
time periods with 10 nM estradiol and the impact on PAX2 gene expression were determined using RT-PCR. GAPDH was used as a control to
normalize for total mRNA content. C-D) MCF-7 cells were treated with 10 nM estradiol for 1 h and subcellular localization of PAX2 was
determined using immunofluorescence (C) and subcellular fractionation (D). In C), Hoescht dye was used to visualize cell nuclei; magnification:
400×. In D), ERa was used as a positive control for estradiol-induced nuclear import, PARP was used as a marker of nuclear fraction (N) purity,
and GAPDH was used as a marker of cytosolic fraction (C) purity. E) Non-luminal breast cancer cell lines MDA-MB-231 (231) and HS578T were
treated with the indicated doses of estradiol. Following 30 min-treatment with estradiol, PAX2 phosphorylation on ser393 residue and total levels
of PAX2 protein were determined, whereas following 24 h-treatment with estradiol, total levels of ERBB2 protein were determined, using western
blot. GAPDH was used as a control to normalize for protein content. All results are representative of three independent experiments.
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luminal MCF-7 cells.
To further document a relationship between PAX2
activity and cell invasion, we have examined whether
insulin-like growth factor-1 (IGF-1), which positively
regulates ERBB2 expression in luminal cells [24] and
increases the motility and invasiveness of MCF-7 cells
[25,26], regulated PAX2 activation by estradiol in these
cells. Treatment of cells with IGF-1 led to a rapid reduc-
tion of PAX2 phosphorylation (Figure 4a), contrary to
estradiol which increased P-PAX2 levels (Figure 4a).
When IGF-1 and estradiol were combined, PAX2
phosphorylation was reduced (Figure 4a), indicating that
IGF-1 antagonizes the effect of estradiol on PAX2 phos-
phorylation. In agreement, treatment of MCF-7 cells
with IGF-1, alone or in combination with estradiol,
increased ERBB2 protein levels (Figure 4b), as well as
cell invasion (Figure 4c). Altogether, these results
strengthen the inverse relationship between PAX2 activ-
ity and cellular invasion and identify IGF-1 as a negative
regulator of PAX2 activity in luminal breast cancer cells.
To directly address a putative role for PAX2 in estradiol-
induced decrease of cell invasion, we knocked down PAX2
using two different small hairpin RNAs (shRNAs). Both
shRNAs efficiently decreased total and phosphorylated
PAX2 protein levels in MCF-7 cells (Figure 5a), and com-
pletely prevented estradiol from decreasing ERBB2 expres-
sion (Figure 5b). They had no impact on estradiol-induced
cellular proliferation (Figure 5c), and did not induce
cleaved fragments of PARP, a marker of apoptosis (Figure
5d), or increase the number of cells with apoptotic nuclear
morphology (Figure 5e). PAX2 knockdown therefore did
not impact cellular proliferation and viability; however, it
completely abrogated estradiol-induced decrease of cell
invasion (Figure 5F). These results reveal for the first time
a role for PAX2 in the regulation of cell invasion.
Finally, we determined if overexpression of PAX2
could successfully decrease the invasive ability of lumi-
nal cells. Transfection of MCF-7 cells with a plasmid
vector containing PAX2 cDNA increased total levels of
Figure 3 Estradiol negatively regulates PAX2 activity and
invasion in an ERa-dependent manner in MCF-7 cells. A) MCF-7
cells were cultivated in a steroid- and serum-depleted growth
medium and treated with 10 nM estradiol for 24 h before they
were subjected to Matrigel invasion assay. Numbers above bars
indicate total number of cells recovered in the lower chamber at
the end of the assays. Pictures show the density of invasive cells
that reached the porous filter. B-D) MCF-7 cells were cultivated in a
steroid- and serum-depleted growth medium and pretreated with
ERa antagonist ICI 182780 (1 μM) for 1 h before they were treated
with 10 nM estradiol. (B) Following 24 h-treatment with estradiol,
total protein content of ERBB2, and of ERa as a marker of ICI
182780 efficiency, were determined using western blot. GAPDH was
used as a control to normalize for protein content. (C) Following 24
h-treatment with estradiol, cell invasion was determined using
Matrigel invasion assay. (D) Following 30 min-treatment with
estradiol, the extent of phosphorylation of PAX2 on ser393 residue
and total levels of PAX2 protein were determined, using western
blot. GAPDH was used as a control to normalize for protein content.
All results are representative or mean value +/-SD of three
independent experiments. Different subscript letters and * indicate a
statistically significant difference.
Figure 4 IGF-1 antagonizes estradiol-induced activation of
PAX2 in luminal breast cancer cells. MCF-7 cells were cultivated
in a steroid- and serum-depleted growth medium and treated with
10 nM estradiol and/or 30 ng/mL IGF-1, as indicated. A) Following
30 min-treatment with estradiol and/or IGF-1, PAX2 phosphorylation
on ser393 residue and total levels of PAX2 protein were determined
using western blot. GAPDH was used as a control to normalize for
protein content. B) Following 24 h-treatment with estradiol and/or
IGF-1, total levels of ERBB2 protein were assessed, using western
blot. GAPDH was used as a control to normalize for protein content.
C) Following 24 h-treatment with estradiol and/or IGF-1, cells were
subjected to Matrigel invasion assay. All results are representative or
mean values +/- SD of three independent experiments. Different
subscript letters indicate a statistically significant difference.
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phosphorylated in response to estradiol and ERBB2 pro-
tein content was efficiently decreased (Figure 6a). Over-
expression of PAX2 inhibited estradiol-induced cellular
proliferation (Figure 6b), but did not induce the cleavage
of PARP (Figure 6c) or increase the number of cells
with apoptotic nuclear morphology (Figure 6d). It
enhanced, on the other hand, estradiol-induced decrease
of ERBB2 protein content (Figure 6a) and cell invasion
(Figure 6e), showing that specific delivery of PAX in
luminal cells exposed to estradiol efficiently reduces
their invasive ability.
Discussion
Multiple factors influence the metastatic outcome of a
cancer, many of them extending beyond intrinsic
tumour cell properties. Nonetheless, it is now recog-
n i z e dt h a ta sag r o u p ,l u m i n a l primary breast tumours
Figure 5 Knockdown of PAX2 abrogates estradiol-induced
decrease of cell invasion in luminal breast cancer cells. MCF-7
cells were cultivated in a steroid- and serum-depleted growth
medium, transfected with PAX2 shRNAs, control shRNA (Ctl:
scrambled sequence from PAX2 shRNA #600) or transfection
reagent only (None) for 24 h and then treated with 10 nM estradiol.
A) PAX2 phosphorylation on ser393 residue and total levels of PAX2
protein were determined using western blot after 30 min of
treatment with estradiol. B) Total levels of ERBB2 was determined
following 24 h-treatment with estradiol. GAPDH was used as a
control to normalize for protein content. C-D) Following treatment
with estradiol for the indicated times, cell proliferation was
determined, using MTT assay (C), and the presence of cleaved
fragments of PARP was assessed using western blot (D). Positive
control for PARP cleavage was MCF-7 cells treated with 10 μM
cisplatin for 24 h. E-F) Following 24 h-treatment with estradiol, cell
nuclei were stained with Hoechst dye and number of apoptotic
cells was determined under a fluorescent microscope (E), and cells
were subjected to Matrigel invasion assay (F). All results are
representative or mean value +/-SD of three independent
experiments; different subscript letters indicate a statistically
significant difference.
Figure 6 Overexpression of PAX2 enhances estradiol-induced
decrease of cell invasion in luminal breast cancer cells. MCF-7
cells were cultivated in a steroid- and serum-depleted growth
medium, transfected with PAX2 cDNA or empty vector and then
treated with 10 nM estradiol. A) Following 30 min-treatment with
estradiol, PAX2 phosphorylation on ser393 residue and total levels
of PAX2 protein were determined (se: short exposition time, to
ensure comparable levels of exogenous PAX2 protein between
PAX2-transfected cells treated with estradiol or not; le: long
exposure time, to detect endogenous PAX2 protein in empty
vector-transfected cells), whereas following 24 h-treatment with
estradiol, total levels of ERBB2 protein were determined, using
western blot. GAPDH was used as a control to normalize for protein
content. Results are representative of three independent
experiments. B) Following treatment with estradiol for the indicated
times, cell proliferation was determined, using MTT assay. Results are
mean +/- SD of four independent experiments. *statistically
significant difference. C) Following treatment with estradiol for the
indicated times, the presence of cleaved fragments of PARP was
assessed using western blot. Positive control for PARP cleavage was
MCF-7 cells treated with 10 μM cisplatin for 24 h. D) Following 24
h-treatment with estradiol, cell nuclei were stained with Hoechst
dye and number of apoptotic cells was determined under a
fluorescent microscope. E) Following 24 h-treatment with estradiol,
cells were subjected to Matrigel invasion assay. In C-E, results are
representative or mean value +/-SD of three independent
experiments. *statistically significant difference.
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sive and metastatic behavior [2,3,27,28]. Identifying key
molecules and mechanisms, which prevent luminal
tumours cells from evolving towards an aggressive meta-
static phenotype, should foster the development of new
anti-metastatic strategies.
The presence of PAX2 in breast tumours has been
d e s c r i b e dm a n yy e a r sa g o[ 1 4 , 1 6 ] ,b u tt h er o l eo ft h e
transcription factor in these tumours remained
unknown until recently, when PAX2 was shown to dic-
tate the response of luminal breast cancer cells to
tamoxifen [17]. In the present study, we describe a new
role for PAX2 in luminal breast cancer cells, as a nega-
tive regulator of cell invasiveness. Because the majority
of breast cancer patients bear luminal tumours [29],
these new informations have important clinical rele-
vance. Further, we provide proof-of-concept for the effi-
ciency of PAX2 overexpression to decrease cell invasion.
We observed that PAX2 overexpression also prevented
estradiol from inducing the proliferation of luminal
breast cancer cells and therefore, apart from interfering
with the metastatic progression of the disease, therapeu-
tic overexpression of PAX2 could induce cytostatic
effects in pre-existing primary and metastatic breast
tumours. Available clinical data indeed suggests an
inverse relationship between PAX2 activity and the pro-
liferation of breast cancer cells in vivo:l o w e rP A X 2
immunoreactivity can be detected in the nucleus of cells
from high grade breast tumours compared to low grade
tumours [14].
Considering such a key role for PAX2 in the control
of luminal breast cancer cell invasiveness, understanding
the mechanisms regulating its activity is primordial. We
show here that PAX2 protein is activated by estradiol, in
breast cancer cells of the luminal subtype only, in agree-
ment with clinical data showing preferential activation
of PAX2 in tumours of the luminal subgroup in vivo
[14,15]. ERa is required for estradiol to induce PAX2
activation; it is also required for estradiol to decrease
ERBB2 expression and cellular invasion, in agreement
with previous studies showing that antagonizing ERa
increases the invasiveness of MCF-7 cells [30]. It is
worth noting that in luminal breast cancer cells, expo-
sure to estradiol has no impact on total PAX2 mRNA
and protein levels; in addition, total levels of PAX2 pro-
tein are comparable in luminal versus non-luminal
breast cancer cells in vitro, similar to clinical data show-
ing the presence of PAX2 in luminal as well as non-
luminal tumours in vivo [14,15]. Therefore, transcription
would not be a major level of regulation for PAX2 in
breast cancer cells, compared to post-translational modi-
fication of the protein. Finally, we have identified a first
negative regulator of PAX2 activity in luminal breast
cancer cells, IGF-1. The inhibition of anti-invasive
factors such as PAX2 may contribute to the pro-invasive
and pro-metastatic effects of IGF-1 in breast cancer
cells [25].
Results from previous reports indirectly suggested that
exposure to estradiol negatively regulates breast cancer
cell invasion: overexpression of ERa in non-luminal
breast cancer cells decrease their invasive ability [31]
and conversely, exposure to anti-oestrogens such as
tamoxifen can increase the invasive ability of ERa+
breast cancer cells [32]. Indeed, although the main effect
attributed to tamoxifen is growth inhibition, it has also
been shown to induce an invasive phenotype in breast
cancer cells, notably by inducing the expression of
matrix metalloproteinases as described in cultivated
MCF-7 cells [33]. The results from the present study
now directly demonstrate that exposure to estradiol has
an opposite effect to tamoxifen and inhibits the invasion
of breast cancer cells, at least for those of the luminal
subtype. It may appear contradictory that estradiol,
which initially promotes the development of luminal
(estrogen-responsive) breast tumours by increasing the
proliferation of breast epithelial cells [34,35], would later
repress the invasion and metastasis of established lumi-
nal tumour cells. However, available clinical data sup-
ports this paradigm. It was reported, for example, that
women using hormone replacement therapy (HRT) had
an increased risk of developing breast cancer, but those
who did develop a breast cancer presented with more
localized tumours and had a more favorable prognosis
than women who did not use HRT [32]. Also, in
patients with ERa+ breast tumours presenting with
metastasis, administration of estradiol pills induced clin-
ical benefits: most patients had longer progression free
survival [36]. In the light of the present work, it is likely
that PAX2 activation and downregulation of ERBB2
expression directly contributes to these beneficial effects
of estradiol.
Conclusion
Identifying PAX2 as a natural barrier against invasion
(and possibly, metastasis) in ERa+/luminal breast cancer
cells, and showing that overexpression of PAX2, when it
is followed by its activation, is sufficient to reduce cellu-
lar invasiveness of luminal breast cancer cells, is of clini-
cal relevance considering that the majority of patients
with breast cancer present with a luminal tumour and
that metastasis is the main cause of death in breast can-
cer patients. It also has the potential to be extended to
non-luminal tumours, even though estrogen signaling is
disrupted in ERa- tumour cells. Indeed, the mechanisms
underlying ERa downregulation in non-luminal breast
cancer cells have already been scrutinized and several
promising strategies to restore ERa expression are cur-
rently under evaluation (reviewed in [36,37]). Therefore,
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pies, designed to re-express ERa and to overexpress
P A X 2a tt h es a m et i m ei nn o n - l u m i n a lb r e a s tc a n c e r
cells, capable of efficiently interfering with progression
of the disease towards metastasis.
Methods
Cell lines and reagents
Human breast carcinoma cell lines (ERa-positive MCF-7
and ZR-75-1 cells and ERa-negative MDA-MB-231 and
HS578T cells) were generously provided by Dr Eric Asse-
lin (University of Quebec in Trois-Rivières, QC, Canada),
who had initially purchased the cell lines from ATCC. All
cell lines were routinely maintained in RPMI-1640 med-
ium containing 50 μg/ml gentamycin, and supplemented
with bovine growth serum (10% for MCF-7 cells and 5%
for MDA-MB-231 and HS578T cells) or fetal bovine
serum (10% for ZR-75-1 cells). All antibodies were from
Cell Signaling Technology (Beverly, MA, USA) except for
HRP-conjugated goat anti-rabbit secondary antibody (Bio-
Rad Laboratories, Mississauga, ONT, Canada), ERa (Ab-
16 from Neomarkers, Thermo Fisher Scientific, Fremont,
CA, USA), PAX2 (sc-130387 from Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA) and phospho-PAX2 (71-6000
from Invitrogen, Burlington, ONT, Canada) antibodies.
Estradiol and recombinant human IGF-1 were purchased
from Sigma-Aldrich (Oakville, ONT, Canada) and ERa
antagonist ICI 182780 was purchased from Cedarlane
Laboratories (Burlington, ONT, Canada).
Cell treatments
Before treatments with estradiol, cells were progressively
adapted to medium depleted of growth factors, steroid
hormones, and estradiol-mimicking molecules such as
phenol red. Specifically, cells were seeded in 6-well
plates (1 × 10
6 cells per well for MCF-7 and HS578T
cells, and 3 × 10
6 cells per well for ZR-75-1 and MDA-
MB-231 cells) and allowed to adhere and proliferate in
standard medium containing serum for 72 h. They were
washed twice with PBS and incubated for 24 h in
RPMI-1640 without phenol red containing 2% dextran-
charcoal treated fetal bovine serum. Finally, cells were
washed and incubated for 24 h in RPMI-1640 without
phenol red or serum. Then, cells were treated with
estradiol (10 nM or as indicated), or with vehicle
(dimethylformamide), in RPMI-1640 without phenol
red. When needed, they were pre-treated with 1 μM ICI
282 780 or with vehicle (DMSO) for 1 h before estradiol
treatment. In all cases, adherent and floating cells were
collected at the end of the treatment.
Western blots analysis
Treated cells were disrupted in cold RIPA buffer contain-
ing protease inhibitors (Complete™ from Roche, Laval,
Quebec, Canada), followed by three freeze-thaw cycles.
Equal amounts of cell lysates were separated onto 10%
polyacrylamide gels and then transferred onto nitrocellu-
lose membranes (Bio-Rad). The membranes were probed
with primary antibody overnight at 4°C and incubated
with horseradish peroxidase-conjugated secondary anti-
body for 45 min. Detection was performed using Super-
Signal West Femto substrate (Pierce, Arlington Heights,
IL, USA), as described by the manufacturer.
Immunofluorescence analysis
Cells were grown on glass coverslips before they were
treated as described above. Treated cells were fixed with
4% paraformaldehyde for 10 min, washed twice in phos-
phate buffered saline (PBS) and permeabilized for 10
min in citrate solution (0.1% sodium citrate, 0.1% Triton
X - 1 0 0i nP B S )a tr o o mt e m p e r a t u r e .T h e yw e r ei n c u -
bated at room temperature for 1 h with primary anti-
body (PAX2, #71-6000 from Invitrogen, diluted 1/20 in
PBS), then for 30 min at room temperature and in the
d a r kw i t hs e c o n d a r ya n t i b o d y( A l e x aF l u o r4 8 8 - c o n j u -
gated donkey anti-rabbit IgG antibody, A-21206 from
Invitrogen, diluted 1/200 in PBS). Cell nuclei were coun-
terstained with 0.25 mg/mL Hoechst dye (Sigma) for 3
min, before coverslips were added onto cells. Stained
cells were visualized under a fluorescence microscope.
RT-PCR analysis of PAX2 expression
Total RNA was isolated from treated MCF-7 cells using
Trizol Reagent (Invitrogen,B u r l i n g t o n ,O N ,C a n a d a )
according to manufacturer’s instructions. First strand
cDNA was synthesized from 0.4 μg RNA using MMLV
reverse transcriptase (Invitrogen). Primers for PCR
amplification of PAX2 were 5’- GTACTACGAGACC
GGCAGCATC-3’ (sense) and 5’- CGTTTCCTCTT
CTCACCATTGG-3’ (antisense) and primers for amplifi-
cation of GAPDH were 5’-gtcagtggtggacctgacct-3’
(sense) and 5’-tgagcttgacaaagtggtcg-3’ (antisense). PCR
reactions were conducted in a MJ Research Thermal
cycler (model PTC-100), using the following parameters:
30 sec. at 94°C, 30 sec. at 58°C, and 1 min. at 72°C, for
35 cycles (PAX2) or 25 cycles (GAPDH). The reaction
mixtures were size-separated on an agarose gel and
visualized using SYBR-SafeTM (Invitrogen) staining
upon ultraviolet transillumination.
Subcellular fractionation
NE-PER Nuclear and Cytoplasmic Extraction Reagent
(Thermo Fisher Scientific) was used according to the
manufacturer’s instructions.
Matrigel invasion assay
The invasive properties of treated cells were measured
using Matrigel-coated Transwell inserts (Costar,
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were coated with 2 mg/ml Matrigel (VWR, Mississauga,
ON, Canada), and treated cells were collected, washed,
and resuspended in respective basal medium without
serum or phenol red. The lower chambers were filled
with 600 μl of respective culture medium, and 2 × 10
5
cells were added to the upper chamber inserts. The
plates were incubated for 72 h at 37°C. After this incu-
bation period, invasive cells had crossed the porous bar-
rier and reached the lower compartment (as previously
reported by others [38,39]). Medium filling the lower
chamber was collected, and invasive cells were recovered
by centrifugation (1 min at 6,000 × g) before they were
resuspended in 30 μl of PBS and counted using a hemo-
cytometer. A percentage of cell invasion was calculated
from the ratio of total number of cells recovered from
the lower compartment to the total number of cells
initially loaded in the upper compartment. To obtain
the pictures presented in A, Matrigel was removed/
wiped away from the filters after 24 h incubation, and
cells having reached the filters at this time point were
f i x e dw i t hc o l dm e t h a n o la n ds t a i n e dw i t hH o e c h s t
33258 dye (Sigma). Pictures were taken under a fluores-
cence microscope (magnification: 100×).
Transfection with vectors encoding PAX2 shRNAs or
cDNA
MCF-7 cells were seeded in 6-well plates at the required
density to reach approximately 60% confluency after 24
h. The day of transfection, PAX2 shRNA constructs or
PAX2 cDNA constructs were added to cells using a
ratio of 3.6 μLF u g e n e : 1 . 2μg DNA/well. Transfection
reagent alone was also separately added as a control
treatment, using the same dilution as described above.
After 8 h-transfection, medium was replaced and plates
were incubated for 40 additional hours (total: 48 h) at
37°C before cells were used for subsequent treatment
with estradiol. PAX2 shRNA constructs were: 5’-G A G -
GAAACGTGATGAAGAT-3’ for PAX2 shRNA #600;
5’-CCCAGCAGCAGCTGGAAGC-3’ for PAX2 shRNA
#701; 5’-GCAATGACGCAGGTGACCA-3’ for control
(Ctl) shRNA (scrambled sequence from PAX2 shRNA
#600). All shRNAs were inserted into pSilencer 1.0-U6
vector; the constructs were a kind gift from Dr Yoshiko
Takahashi, Nara Institute of Science and Technology,
Nara, JAPAN. The PAX2 cDNA constructs were:
human PAX2 cDNA in pcDNA3.1 vector, or empty vec-
tor as a control. The constructs were a kind gift from
Dr Paul Goodyer, McGill University, Montréal, Qc,
CANADA.
MTT proliferation assay
Cells were transfected with PAX2 cDNA or shRNA con-
structs as described above, with the exception that the
incubation following 8-h transfection period was 24 h
instead of 48 h. They were then trypsinized, counted
and plated in 96-well plates at a density of 1 × 10
4 cells
per well, and incubated for an additional 24 h-period at
37°C, after which they reached 80% confluence. Estradiol
was added to selected wells at the concentration of 10
nM in 100 μl culture medium (total time between initial
transfection and estradiol treatment: 48 h), and plates
were incubated for indicated times at 37°C. MTT
reagent (3-(4,5-Dimethyl-2-thiazolyl), Sigma) was added
to the wells (10 μl of a 0.5% solution in PBS) 3.5 h
before the end of the incubation period, and conversion
of yellow tetrazolium salt to blue thiazol crystals by
metabolically active cells was stopped by adding 100 μl
of a 10% sodium dodecyl sulfate, 0.1% HCl solution to
each well. Plates were incubated overnight at 37°C to
allow complete solubilization of thiazol crystals, and
intensity of blue emission in each well was measured
using FluoStar multiwell plate reader (BMG Labora-
tories, Durham, NC). Percentage of proliferating cells
was calculated as the ratio of optical densities of estra-
diol-treated to control-treated cells.
Determination of apoptosis using Hoechst nuclear
staining
Treated cells were collected, washed twice in PBS, resus-
pended at an approximate density of 2 × 10
5 cells/ml in
PBS containing 1 μg/ml Hoechst 33258 (Sigma) and 2%
formalin and incubated for 24 h at 4 °C, before blind
cell counts of apoptotic cells was carried out under a
fluorescence microscope. At least 200 cells were counted
for each sample, and a percentage of apoptotic cells was
calculated as the ratio of apoptotic cells (with character-
istic apoptotic morphology such as nuclear shrinkage
and condensation) to total cell count.
Statistical analyses
Data were subjected to one-way ANOVA (PRISM soft-
ware version 3.03; GraphPad, San Diego, CA, USA). Dif-
ferences between cell groups were determined by the
Tukey’s test. Statistical significance was accepted when
P < 0.05.
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